Update on the Therapeutic Management of Hepatic Encephalopathy

Abstract

Purpose of Review: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments. Recent Findings: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree l-ornithine l-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. Summary: The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.